HC Wainwright Reaffirms Buy Rating for Aptose Biosciences Inc (APS)
Aptose Biosciences (APS) opened at 1.83 on Thursday. Aptose Biosciences has a 1-year low of $1.05 and a 1-year high of $4.02. The firm’s 50-day moving average price is $1.85 and its 200 day moving average price is $1.58. The firm’s market capitalization is $43.97 million.
In related news, Director Warren Whitehead bought 17,000 shares of the business’s stock in a transaction dated Tuesday, June 27th. The stock was purchased at an average cost of C$1.51 per share, for a total transaction of C$25,670.00. Insiders purchased a total of 72,000 shares of company stock valued at $101,920 over the last 90 days.
Aptose Biosciences Company Profile
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Receive News & Ratings for Aptose Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.